Search results
Atara Biotherapeutics EVP sells shares worth nearly $20k By Investing.com
Investing.com· 12 hours agoAtara Biotherapeutics, Inc. (NASDAQ:ATRA) has reported a recent stock transaction involving one of...
Your Portfolio Is a Garden. Weed It
GuruFocus.com via Yahoo Finance· 20 hours agoCytokinetics Muscular diseases are the focus at Cytokinetics Inc. (NASDAQ:CYTK), a biotechnology firm based in South San Francisco, & ...
CERo Therapeutics (NASDAQ:CERO) Trading Down 2.7%
ETF DAILY NEWS· 3 days agoCERo Therapeutics Holdings, Inc. (NASDAQ:CERO – Get Free Report)’s stock price fell 2.7% on Friday . The company traded as low as $1.08 and last traded at $1.10. 60,817 shares changed hands ...
Day one biopharmaceuticals exec sells over $36k in stock By Investing.com
Investing.com· 4 days agoIn a recent move at Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Samuel C. Blackman, the Head of...
Idea Biosciences CEO sells over $7 million in company stock By Investing.com
Investing.com· 5 days agoYujiro S. Hata, the President and CEO of IDEAYA Biosciences, Inc. (NASDAQ:IDYA), has sold a...
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People...
Benzinga· 5 days ago– Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) – – At week 24, 100% of CT-388